nodes	percent_of_prediction	percent_of_DWPC	metapath
Rizatriptan—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00346	0.00346	CcSEcCtD
Rizatriptan—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Rizatriptan—Flushing—Bleomycin—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Rizatriptan—Anorexia—Fludarabine—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Rizatriptan—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Rizatriptan—Myocardial infarction—Vincristine—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Rizatriptan—Feeling abnormal—Teniposide—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Rizatriptan—Musculoskeletal stiffness—Methotrexate—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Rizatriptan—Chills—Bleomycin—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Rizatriptan—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Rizatriptan—Sweating—Vincristine—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Rizatriptan—Nausea—Mechlorethamine—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Rizatriptan—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Rizatriptan—Urticaria—Teniposide—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Rizatriptan—Body temperature increased—Teniposide—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Rizatriptan—Abdominal pain—Teniposide—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Rizatriptan—Erythema—Bleomycin—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Rizatriptan—Paraesthesia—Fludarabine—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Rizatriptan—Hallucination—Carmustine—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Rizatriptan—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Rizatriptan—Sweating—Mitoxantrone—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Rizatriptan—Dyspnoea—Fludarabine—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Rizatriptan—Dyspepsia—Fludarabine—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Rizatriptan—Dysarthria—Methotrexate—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Rizatriptan—Decreased appetite—Fludarabine—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Rizatriptan—Fatigue—Fludarabine—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Rizatriptan—Hallucination—Vincristine—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Rizatriptan—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Rizatriptan—Pain—Fludarabine—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Rizatriptan—Constipation—Fludarabine—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Rizatriptan—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Rizatriptan—Hypersensitivity—Teniposide—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Rizatriptan—Flushing—Carmustine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Rizatriptan—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Rizatriptan—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Rizatriptan—Asthenia—Teniposide—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Rizatriptan—Pruritus—Teniposide—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Rizatriptan—Arrhythmia—Carmustine—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Rizatriptan—Body temperature increased—Fludarabine—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Rizatriptan—Mental disorder—Carmustine—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Rizatriptan—Erythema—Carmustine—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Rizatriptan—Cough—Bleomycin—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Rizatriptan—Angiopathy—Vincristine—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Rizatriptan—Diarrhoea—Teniposide—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Rizatriptan—Chest pain—Bleomycin—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Rizatriptan—Myalgia—Bleomycin—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Rizatriptan—Discomfort—Bleomycin—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Rizatriptan—Mental disorder—Vincristine—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Rizatriptan—Chills—Mitoxantrone—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Rizatriptan—Urine output increased—Methotrexate—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Rizatriptan—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Rizatriptan—Confusional state—Bleomycin—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Rizatriptan—Vision blurred—Carmustine—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Rizatriptan—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Rizatriptan—Tremor—Carmustine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Rizatriptan—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Rizatriptan—Oedema—Bleomycin—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Rizatriptan—Erythema—Mitoxantrone—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Rizatriptan—Vomiting—Teniposide—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Rizatriptan—Agitation—Carmustine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Rizatriptan—Asthenia—Fludarabine—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Rizatriptan—Rash—Teniposide—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Rizatriptan—Dermatitis—Teniposide—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Rizatriptan—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Rizatriptan—Headache—Teniposide—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Rizatriptan—Pruritus—Fludarabine—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Rizatriptan—Anorexia—Bleomycin—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Rizatriptan—Agitation—Vincristine—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Rizatriptan—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Rizatriptan—Photosensitivity—Methotrexate—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Rizatriptan—Polyuria—Methotrexate—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Rizatriptan—Diarrhoea—Fludarabine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Rizatriptan—Convulsion—Carmustine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Rizatriptan—Hypertension—Carmustine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Rizatriptan—Nausea—Teniposide—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Rizatriptan—Vertigo—Vincristine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Rizatriptan—Myalgia—Carmustine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Rizatriptan—Chest pain—Carmustine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Rizatriptan—Anxiety—Carmustine—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Rizatriptan—Paraesthesia—Bleomycin—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Rizatriptan—Dyspnoea—Bleomycin—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Rizatriptan—Convulsion—Vincristine—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Rizatriptan—Hypertension—Vincristine—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Rizatriptan—Confusional state—Carmustine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Rizatriptan—Oedema—Carmustine—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Rizatriptan—Decreased appetite—Bleomycin—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Rizatriptan—Myalgia—Vincristine—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Rizatriptan—Cough—Mitoxantrone—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Rizatriptan—Vomiting—Fludarabine—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Rizatriptan—Convulsion—Mitoxantrone—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Rizatriptan—Rash—Fludarabine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Rizatriptan—Dermatitis—Fludarabine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Rizatriptan—Hypertension—Mitoxantrone—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Rizatriptan—Pain—Bleomycin—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Rizatriptan—Headache—Fludarabine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Rizatriptan—Tachycardia—Carmustine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Rizatriptan—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Rizatriptan—Chest pain—Mitoxantrone—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Rizatriptan—Myalgia—Mitoxantrone—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Rizatriptan—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Rizatriptan—Anxiety—Mitoxantrone—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Rizatriptan—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Rizatriptan—Discomfort—Mitoxantrone—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Rizatriptan—Oedema—Vincristine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Rizatriptan—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Rizatriptan—Anorexia—Carmustine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Rizatriptan—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Rizatriptan—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Rizatriptan—Confusional state—Mitoxantrone—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Rizatriptan—Nervous system disorder—Vincristine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Rizatriptan—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Rizatriptan—Oedema—Mitoxantrone—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Rizatriptan—Nausea—Fludarabine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Rizatriptan—Hyperhidrosis—Vincristine—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Rizatriptan—Shock—Mitoxantrone—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Rizatriptan—Urticaria—Bleomycin—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Rizatriptan—Anorexia—Vincristine—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Rizatriptan—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Rizatriptan—Body temperature increased—Bleomycin—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Rizatriptan—Insomnia—Carmustine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Rizatriptan—Irritability—Methotrexate—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Rizatriptan—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Rizatriptan—Paraesthesia—Carmustine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Rizatriptan—Dyspnoea—Carmustine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Rizatriptan—Somnolence—Carmustine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Rizatriptan—Anorexia—Mitoxantrone—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Rizatriptan—Ataxia—Methotrexate—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Rizatriptan—Decreased appetite—Carmustine—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Rizatriptan—Insomnia—Vincristine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Rizatriptan—Paraesthesia—Vincristine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Rizatriptan—Constipation—Carmustine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Rizatriptan—Pain—Carmustine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Rizatriptan—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Rizatriptan—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Rizatriptan—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Rizatriptan—Decreased appetite—Vincristine—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Rizatriptan—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Rizatriptan—Somnolence—Mitoxantrone—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Rizatriptan—Feeling abnormal—Carmustine—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Rizatriptan—Fatigue—Vincristine—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Rizatriptan—Asthenia—Bleomycin—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Rizatriptan—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Rizatriptan—Pain—Vincristine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Rizatriptan—Constipation—Vincristine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Rizatriptan—Pruritus—Bleomycin—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Rizatriptan—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Rizatriptan—Fatigue—Mitoxantrone—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Rizatriptan—Pain—Mitoxantrone—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Rizatriptan—Constipation—Mitoxantrone—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Rizatriptan—Abdominal pain—Carmustine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Rizatriptan—Body temperature increased—Carmustine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Rizatriptan—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Rizatriptan—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Rizatriptan—Dysuria—Methotrexate—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Rizatriptan—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Rizatriptan—Body temperature increased—Vincristine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Rizatriptan—Abdominal pain—Vincristine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Rizatriptan—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Rizatriptan—Urticaria—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Rizatriptan—Hypersensitivity—Carmustine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Rizatriptan—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Rizatriptan—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Rizatriptan—Vomiting—Bleomycin—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Rizatriptan—Rash—Bleomycin—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Rizatriptan—Dermatitis—Bleomycin—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Rizatriptan—Asthenia—Carmustine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Rizatriptan—Hypersensitivity—Vincristine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Rizatriptan—Sweating—Methotrexate—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Rizatriptan—Epistaxis—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Rizatriptan—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Rizatriptan—Asthenia—Vincristine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Rizatriptan—Diarrhoea—Carmustine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Rizatriptan—Nausea—Bleomycin—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Rizatriptan—Asthenia—Mitoxantrone—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Rizatriptan—Dizziness—Carmustine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Rizatriptan—Diarrhoea—Vincristine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Rizatriptan—Pharyngitis—Methotrexate—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Rizatriptan—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Rizatriptan—Vomiting—Carmustine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Rizatriptan—Dizziness—Vincristine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Rizatriptan—Rash—Carmustine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Rizatriptan—Dermatitis—Carmustine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Rizatriptan—Headache—Carmustine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Rizatriptan—Tinnitus—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Rizatriptan—Vomiting—Vincristine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Rizatriptan—Rash—Vincristine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Rizatriptan—Dermatitis—Vincristine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Rizatriptan—Headache—Vincristine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Rizatriptan—Nausea—Carmustine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Rizatriptan—Angiopathy—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Rizatriptan—Vomiting—Mitoxantrone—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Rizatriptan—Rash—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Rizatriptan—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Rizatriptan—Chills—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Rizatriptan—Headache—Mitoxantrone—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Rizatriptan—Mental disorder—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Rizatriptan—Erythema—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Rizatriptan—Nausea—Vincristine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Rizatriptan—Dysgeusia—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Rizatriptan—Nausea—Mitoxantrone—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Rizatriptan—Vision blurred—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Rizatriptan—Vertigo—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Rizatriptan—Cough—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Rizatriptan—Convulsion—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Rizatriptan—Chest pain—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Rizatriptan—Myalgia—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Rizatriptan—Arthralgia—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Rizatriptan—Discomfort—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Rizatriptan—Confusional state—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Rizatriptan—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Rizatriptan—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Rizatriptan—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Rizatriptan—Anorexia—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00096	0.00096	CcSEcCtD
Rizatriptan—Insomnia—Methotrexate—lymphatic system cancer	0.000953	0.000953	CcSEcCtD
Rizatriptan—Paraesthesia—Methotrexate—lymphatic system cancer	0.000946	0.000946	CcSEcCtD
Rizatriptan—Dyspnoea—Methotrexate—lymphatic system cancer	0.000939	0.000939	CcSEcCtD
Rizatriptan—Somnolence—Methotrexate—lymphatic system cancer	0.000937	0.000937	CcSEcCtD
Rizatriptan—Dyspepsia—Methotrexate—lymphatic system cancer	0.000928	0.000928	CcSEcCtD
Rizatriptan—Decreased appetite—Methotrexate—lymphatic system cancer	0.000916	0.000916	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00091	0.00091	CcSEcCtD
Rizatriptan—Fatigue—Methotrexate—lymphatic system cancer	0.000908	0.000908	CcSEcCtD
Rizatriptan—Pain—Methotrexate—lymphatic system cancer	0.000901	0.000901	CcSEcCtD
Rizatriptan—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000868	0.000868	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000862	0.000862	CcSEcCtD
Rizatriptan—Urticaria—Methotrexate—lymphatic system cancer	0.000837	0.000837	CcSEcCtD
Rizatriptan—Abdominal pain—Methotrexate—lymphatic system cancer	0.000833	0.000833	CcSEcCtD
Rizatriptan—Body temperature increased—Methotrexate—lymphatic system cancer	0.000833	0.000833	CcSEcCtD
Rizatriptan—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000776	0.000776	CcSEcCtD
Rizatriptan—Asthenia—Methotrexate—lymphatic system cancer	0.000756	0.000756	CcSEcCtD
Rizatriptan—Pruritus—Methotrexate—lymphatic system cancer	0.000746	0.000746	CcSEcCtD
Rizatriptan—Diarrhoea—Methotrexate—lymphatic system cancer	0.000721	0.000721	CcSEcCtD
Rizatriptan—Dizziness—Methotrexate—lymphatic system cancer	0.000697	0.000697	CcSEcCtD
Rizatriptan—Vomiting—Methotrexate—lymphatic system cancer	0.00067	0.00067	CcSEcCtD
Rizatriptan—Rash—Methotrexate—lymphatic system cancer	0.000664	0.000664	CcSEcCtD
Rizatriptan—Dermatitis—Methotrexate—lymphatic system cancer	0.000664	0.000664	CcSEcCtD
Rizatriptan—Headache—Methotrexate—lymphatic system cancer	0.00066	0.00066	CcSEcCtD
Rizatriptan—Nausea—Methotrexate—lymphatic system cancer	0.000626	0.000626	CcSEcCtD
